Key result
Carriers of CYP2C9*2 or *3 alleles had an increased risk of severe overanticoagulation during phenprocoumon initiation compared with wild-type subjects (HR 3.09 and 2.40, respectively).
Why the study?
Do CYP2C9*2 or *3 alleles increase the risk of severe overanticoagulation in patients starting phenprocoumon compared to wild-type alleles?
Cohort (n=284)
Yes
Do CYP2C9*2 or *3 alleles increase the risk of severe overanticoagulation in patients starting phenprocoumon compared to wild-type alleles?
Hazard Ratio: 3.09 (95% CI 1.56–6.13)
p-value: p=0.001
Carriers of CYP2C9*2 or *3 alleles require lower phenprocoumon doses and are at significantly higher risk of severe overanticoagulation during the initial phase of treatment compared to wild-type carriers.
No takes yet. Share an insight, caveat, or question.
May support closer monitoring or dose adjustment in variant carriers; leaves open whether genotyping improves outcomes in practice.
Schalekamp et al. (2004) conducted a cohort in Anticoagulation therapy (n=284). CYP2C9*2 or CYP2C9*3 alleles vs. Homozygous CYP2C9*1/*1 (wild-type) allele was evaluated on Severe overanticoagulation (INR >6.0) (HR 3.09, 95% CI 1.56-6.13, p=0.001). Carriers of CYP2C9*2 or *3 alleles had an increased risk of severe overanticoagulation during phenprocoumon initiation compared with wild-type subjects (HR 3.09 and 2.40, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: